Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
A man in a purple shirt grips one wrist with his other hand against a white brick wall.

Fabry Disease Treatments Compared

3 FDA-approved drugs, plus 2 in development, side by side from the current prescribing labels. Newest label Aug 2025. Checked November 3, 2026.

The full Fabry Disease guide, with open trials and help paying →

Enzyme replacement infusionsFabrazyme · Elfabrio
Chaperone pill (amenable variants only)Galafold

Three drugs are FDA-approved for Fabry disease, 2 enzyme replacement infusions and 1 capsule.

  • Fabrazyme (agalsidase beta) and Elfabrio (pegunigalsidase alfa) are infusions given every 2 weeks.
  • Galafold (migalastat) is a capsule taken every other day, approved only for people whose GLA gene variant is amenable to it.
  • Fabrazyme is the only one approved for children, from age 2; Elfabrio and Galafold are for adults.
  • Elfabrio is the only drug tested head to head, against Fabrazyme in people already taking it, and kidney function declined at nearly the same rate on both over 2 years.
  • Both infusions carry a boxed warning for severe allergic reactions including anaphylaxis. Galafold has no boxed warning, holds accelerated approval and is not recommended with severe kidney impairment.

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Email me the day the FDA decides on ST-920

You get one email when the decision is public, plus new trials and FDA news for this condition.

You'll get trial alerts and disease updates for Fabry Disease, and you can turn either off anytime. We never share your email. Privacy policy

Side by side

3 approved Fabry disease treatments at a glance

How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.

Fabry Disease treatments compared: route, schedule, approved use and approval date
DrugHow it is givenHow oftenApproved forFirst approved
agalsidase beta
Sanofi (Genzyme)
IV infusion every 2 weeks, started in a healthcare settingAbout 90 minutes per dose1mg/kg by IV infusion every 2 weeks, starting at 0.25mg per minute and sped up as tolerated to a minimum of 1.5 hoursAdults and children 2 and older with confirmed Fabry diseaseApril 24, 2003
pegunigalsidase alfa
Chiesi (developed with Protalix)
IV infusion every 2 weeksAbout 90 minutes per dose1mg/kg by IV infusion every 2 weeks; the first 4 to 6 infusions run at set rates by body weight, then can be shortened to a minimum of 1.5 hoursAdults with confirmed Fabry diseaseMay 9, 2023
migalastat
Amicus Therapeutics (BioMarin)
1 capsule every other day by mouth, on an empty stomach123mg capsule every other day at the same time of day, with no food or caffeine for 2 hours before and 2 hours afterAdults with confirmed Fabry disease and an amenable GLA gene variant, under accelerated approvalAugust 10, 2018
The calendar

A year on each Fabry disease treatment

Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.

Fabrazyme
Infusion, at a clinic
26 doses a year
Elfabrio
Infusion, at a clinic
26 doses a year
Galafold
By mouth, at home
183 doses a year

Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.

The evidence

What the pivotal Fabry disease trials showed

The primary result from the trial each FDA approval rests on, as reported on the label.

Fabry Disease pivotal trial results by drug
DrugPivotal trialPrimary result
agalsidase beta
Sanofi (Genzyme)
Study 1, 58 people aged 16 to 61 who had never had enzyme replacement20 of 29 (69%) on Fabrazyme cleared GL-3 deposits from small kidney blood vessels at 20 weeks vs 0 of 29 on placebo
pegunigalsidase alfa
Chiesi (developed with Protalix)
BALANCE (Trial 2), 77 adults already on Fabrazyme for at least 1 year, Elfabrio vs Fabrazyme for 2 years
Trial record or paper
Kidney function (eGFR) declined 2.4mL/min per year on Elfabrio and 2.3 on Fabrazyme, a difference of -0.1 (95% CI -2.3 to 2.1)
migalastat
Amicus Therapeutics (BioMarin)
FACETS (Study 1), 67 adults, of whom 50 had amenable variants
Trial record or paper
52% on Galafold vs 45% on placebo had at least a 50% drop in kidney GL-3 at 6 months (13 of 25 vs 9 of 20); in men, 71% vs 44%
Safety

Fabry Disease treatment side effects and warnings

Fabrazyme and Elfabrio carry a boxed warning, the FDA's strongest. The rest list their main precautions. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.

Fabry Disease treatments: most common side effects and key warnings from the FDA labels
DrugMost common side effectsKey warning
agalsidase beta
Sanofi (Genzyme)
infusion reactions 59%, upper respiratory infection 53%, chills 49% and fever 39%Boxed warning Boxed warning for life-threatening allergic reactions including anaphylaxis. Start in a healthcare setting with emergency equipment; premedication with antihistamines, fever reducers or steroids may be used.
pegunigalsidase alfa
Chiesi (developed with Protalix)
infusion reactions 32% vs 32% on Fabrazyme, common cold symptoms 21% vs 16%, headache 21% vs 20% and diarrhea 19% vs 24%Boxed warning Boxed warning for allergic reactions including anaphylaxis. The label also warns about membranoproliferative glomerulonephritis, a kidney inflammation reported in 1 patient; kidney tests should be monitored.
migalastat
Amicus Therapeutics (BioMarin)
headache 35%, common cold symptoms 18%, urinary tract infection 15% and nausea 12%No boxed warning and no warnings section on the label. Only for amenable GLA variants; not recommended with severe kidney impairment (eGFR below 30) or dialysis.
Not yet approved

Fabry disease treatments in Phase 3 or under FDA review

Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.

Fabry Disease drugs not FDA-approved
DrugStatusHow it works and is givenPivotal trialResult so farWhat is next
Phase 3as of November 3, 2026Oral pill that slows production of the fatty substance that builds up in Fabry disease (substrate reduction)Tablet by mouth once a dayCARAT, Phase 3, 104 adults with thickened heart muscle, vs usual carePrimary endpoint: Change in left ventricular mass index on cardiac MRI
ClinicalTrials.gov
Did not meet its primary endpoint (Sanofi, July 30, 2026). A separate Phase 3, PERIDOT (122 people), missed its pain endpoint because pain fell in both groups (Sanofi, February 2, 2026)Sanofi removed venglustat for Fabry from its Phase 3 pipeline; long-term extensions of CARAT and PERIDOT continue (Sanofi, July 30, 2026)
Sanofi Q2 2026 results press release, July 30, 2026
PTC Therapeutics (developed by Sangamo Therapeutics)
Phase 3as of November 8, 2026One-time gene therapy that delivers a working GLA gene so the body makes its own alpha-galactosidase A enzymeSingle IV infusionSTAAR, Phase 1/2, open label, 32 adults dosed, no comparison groupPrimary endpoint: Registry main measure: side effects up to 12 months. The application uses the 52-week eGFR slope as an intermediate endpoint for accelerated approval
ClinicalTrials.gov
Average yearly eGFR change of +1.965mL/min/1.73m² at 52 weeks across 32 patients (95% CI -0.153 to 4.083); all 18 people who started on enzyme replacement were taken off it (Sangamo, June 24 and September 4, 2025)PTC expects to finish its rolling FDA application in the fourth quarter of 2026 (PTC, October 29, 2026)
PTC Therapeutics Q3 2026 results press release, October 29, 2026
Cost

Help paying for Fabry disease treatment

Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read
Follow Fabry Disease treatment news by email

One email when the FDA acts on a Fabry Disease treatment, a label changes or a new trial opens. Never a newsletter.

You'll get, for Fabry Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Questions

Fabry Disease treatment questions people ask

Fabrazyme vs Elfabrio: what is the difference for Fabry disease?

Both replace the missing alpha-galactosidase A enzyme by IV infusion every 2 weeks at 1mg/kg. Elfabrio is a newer version of the enzyme, made in plant cells and linked to PEG, a coating used to change how a drug behaves in the body.

Who it is for: Fabrazyme covers adults and children 2 and older. Elfabrio covers adults only.

Trial results: Elfabrio is the only Fabry drug tested head to head. In 77 adults already on Fabrazyme, kidney function declined 2.4mL/min per year on Elfabrio and 2.3 on Fabrazyme over 2 years, a difference of 0.1.

Safety: both carry a boxed warning for anaphylaxis. Elfabrio's label also warns about membranoproliferative glomerulonephritis, a kidney inflammation reported in 1 trial patient, and calls for regular kidney tests. Infusion reactions were reported in 32% of people on each drug in the head-to-head trial.

Switching: Elfabrio's label includes starting infusion rates for people coming from another enzyme replacement therapy. Whether to switch is a decision for the treating doctor.

More: Fabrazyme drug page and Elfabrio drug page

Source: FDA label for Fabrazyme, DailyMed, effective August 2025; FDA label for Elfabrio, DailyMed, effective July 2024

Who can take Galafold for Fabry disease?

Adults with confirmed Fabry disease and a GLA gene variant that a lab assay shows is amenable to migalastat. The label recommends a clinical genetics professional review the variant when its meaning is uncertain. Galafold is not recommended for people with severe kidney impairment (eGFR below 30) or on dialysis, and it is not approved for children. It is taken as 1 capsule every other day with no food or caffeine for 2 hours before and after.

Is there a pill for Fabry disease?

Yes, Galafold (migalastat), but only for adults with an amenable GLA variant. Two other pills have reached Phase 3, venglustat from Sanofi and lucerastat from Idorsia. Sanofi said on July 30, 2026 that venglustat missed the main goal of its Phase 3 heart trial, CARAT, after its PERIDOT pain trial missed in February 2026, and that long-term extensions of both trials continue. Sanofi's July 30, 2026 results slides list venglustat for Fabry as removed from its Phase 3 pipeline. Lucerastat's new Phase 3 trial, Fab-Klear (NCT07778667), is enrolling at a Dallas site as of November 2026.

Which Fabry disease treatment is approved for children?

Only Fabrazyme, approved from age 2 since March 2021. Elfabrio and Galafold are approved for adults. Both have pediatric studies recruiting: Elfabrio in children (NCT06328608) and Galafold in children aged 2 to under 12 (NCT06904261).

Are there new Fabry disease treatments in clinical trials?

As of November 2026, the oral drug with an open Phase 3 trial is lucerastat from Idorsia, whose study (NCT07778667) plans about 16 untreated adult men and is enrolling at a Dallas site. Venglustat, an oral drug from Sanofi, missed the main goal of both of its Phase 3 Fabry trials, PERIDOT in February 2026 and CARAT, a heart trial in 104 adults, in results Sanofi reported on July 30, 2026, and long-term extensions of both continue. Sanofi's results slides that day list venglustat for Fabry as removed from its Phase 3 pipeline. ST-920, a one-time gene therapy now owned by PTC Therapeutics, finished its Phase 1/2 trial (NCT04046224), and PTC said on October 29, 2026 that it expects to finish submitting its FDA application in the fourth quarter of 2026. AMT-191, a gene therapy from uniQure, is in a recruiting Phase 1/2 trial (NCT06270316). The 4D-310 gene therapy from 4D Molecular Therapeutics still has a Phase 1/2 record marked recruiting (NCT05629559), but that record was last updated in February 2025 and 4DMT no longer lists 4D-310 on its pipeline page.

Does Fabrazyme slow kidney decline in Fabry disease?

Its label reports 2 kinds of evidence. In a trial of 82 people with more advanced disease, kidney, heart or stroke events or death occurred in 28% on Fabrazyme against 42% on placebo, a difference that was not statistically certain. In an observational comparison of 122 treated people with matched untreated patients, kidney function declined 1.5mL/min per year on Fabrazyme against 3.2 untreated.

Go deeper

More on Fabry Disease at Trial Friend

Sources

Where every number on this page comes from

Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.

  1. Fabrazyme (agalsidase beta) prescribing information, Sanofi (Genzyme), label dated Aug 2025. DailyMed
  2. Elfabrio (pegunigalsidase alfa) prescribing information, Chiesi (developed with Protalix), label dated Jul 2024. DailyMed. Pivotal trial: ClinicalTrials.gov
  3. Galafold (migalastat) prescribing information, Amicus Therapeutics (BioMarin), label dated Aug 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
  4. venglustat, Sanofi: ClinicalTrials.gov record; Sanofi Q2 2026 results press release, July 30, 2026. Checked November 3, 2026.
  5. ST-920 (isaralgagene civaparvovec), PTC Therapeutics (developed by Sangamo Therapeutics): ClinicalTrials.gov record; PTC Therapeutics Q3 2026 results press release, October 29, 2026. Checked November 8, 2026.

This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.